Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry
British Journal of Dermatology · 10.10.2026
DOI: 10.1093/bjd/ljag445 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 10.10.2026. Verfasst von Jürgen C Becker und 18 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Translational Skin Cancer Research and Dermatology, University Medicine Essen, Essen, Germany. Die Arbeit nennt 8 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
This study observed the real-world outcomes with avelumab treatment in patients with Merkel cell carcinoma (MCC) in Germany by immunocompromised status. Objective response rates with avelumab as first-line treatment were similar in immunocompromised and immunocompetent patients; however, long-term survival was shorter in the immunocompromised subgroup. Rates of avelumab-related adverse drug reactions were comparable between the subgroups. These findings demonstrate the clinical activity and safety of avelumab in both immunocompetent and immunocompromised patients with MCC.
Autor:innen und Institutionen
- Departments of Translational Skin Cancer Research and Dermatology, University Medicine Essen, Essen, Germany.
- German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Merck Healthcare KGaA, Darmstadt, Germany.
- Department of Dermatology, University Hospital Essen; German Cancer Consortium, Partner Site Essen; National Center for Tumor Diseases (NCT) West, Campus Essen, Essen, Germany.
- Research Alliance Ruhr - Research Center One Health, University of Duisburg-Essen, Essen, Germany.
- Department of Dermatology, Center for Dermato-Oncology, Eberhard Karls University of Tübingen, Tübingen, Germany.
ORCID-Profile: Jürgen C Becker, Dirk Schadendorf, Stephan Grabbe, Christoffer Gebhardt
Förderung
- Merck
Zitieren
APA
Becker, J. C., Mahmoudpour, S. H., Schadendorf, D., Leiter, U., Meier, F., Herbst, R., Grabbe, S., Gebhardt, C., Ziller, F., Pföhler, C., Mohr, P., Zimmer, L., Boutmy, E., Oksen, D., Kearney, M., Ruth, K., Hoff, S., Shlaen, M., & Ugurel, S. (2026). Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag445
Vancouver
Becker JC, Mahmoudpour SH, Schadendorf D, Leiter U, Meier F, Herbst R, et al. Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag445
BibTeX
@article{Becker2026,
author = {Becker, Jürgen C and Mahmoudpour, Seyed Hamidreza and Schadendorf, Dirk and Leiter, Ulrike and Meier, Friedegund and Herbst, Rudolf and Grabbe, Stephan and Gebhardt, Christoffer and Ziller, Fabian and Pföhler, Claudia and Mohr, Peter and Zimmer, Lisa and Boutmy, Emmanuelle and Oksen, Dina and Kearney, Mairead and Ruth, Katia and Hoff, Sebastian and Shlaen, Margarita and Ugurel, Selma},
title = {Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag445}
}
EUVIMED